An Impossible Pathogen
For most of the 20th century, the central dogma of biology held that infectious agents required genetic material (DNA or RNA) to replicate. Then came prions: infectious agents made entirely of protein, with no nucleic acid at all. They replicate by corrupting normal proteins into copies of themselves, spreading through the brain like a crystallizing wave.[1]
The idea was so radical that Stanley Prusiner, who proposed the "protein-only hypothesis" in 1982, faced years of skepticism and ridicule. He was vindicated with the 1997 Nobel Prize in Physiology or Medicine.
Prion diseases, also called transmissible spongiform encephalopathies (TSEs), are invariably fatal. They turn the brain into a sponge-like mass of holes, destroying neurons and leaving no survivors.
The Mechanism: Molecular Corruption
The prion protein (PrP) is a normal component of cell membranes, particularly abundant in neurons. Its normal form, PrPC (cellular), is predominantly alpha-helical in structure. The function of normal PrP remains somewhat mysterious, though it may be involved in cell signaling and copper metabolism.[2]
The disease form, PrPSc (scrapie), has the same amino acid sequence but a radically different shape, rich in beta-sheets instead of alpha-helices. This misfolded protein has a terrifying property: it can convert normal PrPC into more PrPSc.
- Template-directed misfolding: PrPSc binds to normal PrPC
- Conformational change: PrPC is induced to refold into the PrPSc shape
- Aggregation: Misfolded proteins clump into amyloid fibrils
- Fragmentation: Fibrils break, creating new "seeds" for conversion
- Exponential spread: Process accelerates as more seeds form
The result is accumulation of insoluble protein aggregates that damage and kill neurons. The brain develops characteristic spongiform changes, microscopic holes where neurons have died, giving these diseases their name.
Human Prion Diseases
Human prion diseases are rare but devastating:
Creutzfeldt-Jakob Disease (CJD)
Sporadic CJD accounts for 85% of cases. It arises spontaneously, likely from random misfolding of PrP. Incidence is about 1-2 per million per year worldwide. Patients present with rapidly progressive dementia, myoclonus (muscle jerks), and various neurological signs. Death typically occurs within months of symptom onset.[3]
Familial CJD (10-15% of cases) results from inherited mutations in the PRNP gene encoding PrP. Over 40 different mutations have been identified.
Iatrogenic CJD results from medical transmission through contaminated surgical instruments, corneal transplants, dura mater grafts, or (historically) growth hormone extracted from cadaveric pituitary glands.
Variant CJD (vCJD)
First identified in 1996, vCJD results from eating beef contaminated with bovine spongiform encephalopathy (BSE, "mad cow disease"). Unlike sporadic CJD, which typically strikes the elderly, vCJD affects younger people (median age 28) and has a longer clinical course. The UK saw 178 cases, mostly linked to the BSE epidemic of the 1980s-90s.[4]
Kuru
Kuru was an epidemic prion disease among the Fore people of Papua New Guinea, transmitted through ritualistic cannibalism, specifically, consumption of deceased relatives' brains during funeral rites. At its peak in the 1950s, it was the leading cause of death among Fore women. The practice ended, and kuru has nearly disappeared, though cases occasionally emerged decades later due to incubation periods exceeding 50 years.[5]
Fatal Familial Insomnia (FFI)
FFI is a rare inherited prion disease characterized by progressively worsening insomnia, autonomic dysfunction, and dementia. Patients literally cannot sleep, deteriorating over months into a state of exhausted delirium before death. Fewer than 100 families worldwide carry the mutation.
Gerstmann-Sträussler-Scheinker Syndrome (GSS)
Another inherited prion disease, GSS typically presents with cerebellar ataxia (coordination problems) and progresses more slowly than CJD, over 2-10 years.
Animal Prion Diseases
- Scrapie: Sheep and goats; known for over 250 years
- Bovine Spongiform Encephalopathy (BSE): Cattle; caused the "mad cow" crisis
- Chronic Wasting Disease (CWD): Deer and elk; spreading across North America
- Transmissible Mink Encephalopathy: Farmed mink
- Feline Spongiform Encephalopathy: Cats; linked to BSE-contaminated food
Chronic Wasting Disease is particularly concerning. It is spreading through wild deer and elk populations in North America and has been detected in Scandinavia. While no human cases have been confirmed, the possibility of cross-species transmission cannot be ruled out.
The BSE Crisis
The bovine spongiform encephalopathy epidemic in the United Kingdom was a public health disaster that reshaped food safety worldwide. BSE emerged because cattle were fed meat-and-bone meal containing remains of infected animals. Essentially, cows were being fed cows.[4]
Key events:
- 1986: BSE first identified in UK cattle
- 1989: Specified bovine offals banned from human food
- 1996: Link to human vCJD announced; EU bans British beef exports
- Peak: Over 180,000 cattle diagnosed; millions culled
- Human toll: 178 vCJD deaths in UK, ~230 worldwide
"The BSE crisis showed how prions could leap species barriers with catastrophic consequences, and how industrial agriculture could amplify a rare disease into an epidemic."
Diagnosis
Diagnosing prion disease remains challenging:
- Clinical presentation: Rapidly progressive dementia with myoclonus
- MRI: Characteristic patterns including "cortical ribboning" and basal ganglia abnormalities
- EEG: Periodic sharp wave complexes (in sporadic CJD)
- CSF biomarkers: 14-3-3 protein, RT-QuIC (real-time quaking-induced conversion) assay
- Definitive diagnosis: Brain biopsy or autopsy demonstrating PrPSc
The RT-QuIC assay has been a major advance. It can detect tiny amounts of prion protein in cerebrospinal fluid with high sensitivity and specificity, enabling diagnosis without brain biopsy.
Treatment: The Ultimate Challenge
There is no treatment that can slow, stop, or reverse prion disease. The challenges are formidable:
- Target is a self-protein: Attacking PrPSc risks attacking normal PrPC
- Blood-brain barrier: Drugs must reach the central nervous system
- Late diagnosis: By the time of diagnosis, extensive damage has occurred
- Prion stability: PrPSc is remarkably resistant to degradation
Research approaches under investigation include:
- Antisense oligonucleotides to reduce PrPC production
- Antibodies targeting PrP
- Small molecules preventing PrPSc formation
- Gene therapy approaches
Some patients and families are pursuing experimental treatments, including one couple, a scientist whose wife carries the FFI mutation, racing to develop antisense therapy before she becomes symptomatic.
Infection Control
Prions present unique decontamination challenges. They resist:
- Standard autoclaving
- Formaldehyde
- Alcohol
- Ultraviolet radiation
- Ionizing radiation
Effective decontamination requires extreme measures: concentrated sodium hydroxide or bleach, extended autoclaving at higher temperatures, or incineration. Surgical instruments used on known or suspected prion patients must be destroyed.
Broader Implications
Prions have implications beyond TSEs. The concept of "protein-only" inheritance, information transmitted through protein shape rather than nucleic acid sequence, has been found in yeast and other organisms. Some researchers believe prion-like mechanisms may contribute to other neurodegenerative diseases:
- Alzheimer's disease: Beta-amyloid and tau may spread in prion-like fashion
- Parkinson's disease: Alpha-synuclein shows prion-like propagation
- ALS: TDP-43 and SOD1 aggregates may spread similarly
If these diseases involve prion-like mechanisms, strategies developed against classical prions might have broader applications.
Prion diseases remain among the most terrifying in medicine: invariably fatal, incurable, caused by a pathogen that defies conventional biology. They remind us that nature can find ways to propagate information, and cause disease, that we never imagined.
Sources
- Prusiner, S. B. (1998). Prions. PNAS, 95(23), 13363-13383.
- Aguzzi, A., & Calella, A. M. (2009). Prions: protein aggregation and infectious diseases. Physiological Reviews, 89(4), 1105-1152.
- Geschwind, M. D. (2015). Prion diseases. Continuum, 21(6), 1612-1638.
- Will, R. G. (2003). Acquired prion disease: iatrogenic CJD, variant CJD, kuru. British Medical Bulletin, 66(1), 255-265.
- Collinge, J., et al. (2006). Kuru in the 21st century. Philosophical Transactions of the Royal Society B, 361(1476), 2079-2089.
- CDC. (2023). Prion Diseases. cdc.gov